A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)
| Status: | Terminated |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | January 2008 |
| End Date: | March 2010 |
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 1)
The purpose of this clinical research study is to study the safety of Epofolate (BMS-753493)
in patients with advanced cancers (in Phase 1 portion) and to determine whether Epofolate
(BMS-753493) can shrink or slow the growth of the cancer in patients with advanced ovarian,
renal or breast cancer (in Phase 2 portion).
in patients with advanced cancers (in Phase 1 portion) and to determine whether Epofolate
(BMS-753493) can shrink or slow the growth of the cancer in patients with advanced ovarian,
renal or breast cancer (in Phase 2 portion).
Inclusion Criteria:
- Advanced cancer, excluding cancer in the blood
- Availability of 10 tumor tissue slides
Exclusion:
- Known brain metastases
- Severe nerve damage
- Significant cardiovascular disease
- Inadequate blood counts
- Inadequate liver or kidney function
- Inadequate thyroid function or uncontrolled thyroid disease
We found this trial at
4
sites
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials